刊名:The Journal of Steroid Biochemistry and Molecular Biology
出版年:2017
出版时间:February 2017
年:2017
卷:166
期:Complete
页码:16-27
全文大小:1319 K
卷排序:166
文摘
Androgen deprivation therapy (ADT) is treatment of choice for recurrent PCa. Patients eventually develop CRPC- a more advanced and resistant PCa phenotype. Host of molecular alterations are involved in acquiring resistance to ADT and CRPC. Array of drugs are precisely designed to target aberrant signaling pathways. Review summarizes key aberrant pathways in PCa and therapeutics influencing them.